About Response Biomedical
Response Biomedical is a Healthcare company based in Vancouver (Canada) founded in 1992, and was acquired by Shanghai Runda Medical Technology in June 2016. Rapid on-site diagnostic tests are developed, manufactured, and marketed. Response Biomedical offers products and services including RAMP Tests, RAMP 200, and COVID-19 Antigen Test. Its focus areas include Diversified Diagnostics. Its legal entity is RESPONSE BIOMEDICAL CORP.
Company details
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP platform for clinical and environmental applications. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use. The lateral flow based tests are available for diagnosis of Cardiovascular diseases and Infectious diseases.The RAMP system consists of a reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP clinical tests are commercially available for the early detection of heart attack and congestive heart failure through their commercial partners and distributors. In the non-clinical market, RAMP Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Response has achieved CE Marking for its readers and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.
- Headquarters Vancouver, Canada
- Stage Acquired
- SectorsHealthcare
- Website responsebio.com
- Social LinkedIn X Facebook YouTube
- Acquired by Shanghai Runda Medical Technology (Jun 2016)
- Legal Name Response Biomedical Corp
- Latest Funding Round$3.12M (USD), Post-IPO
Oct 2013
- InvestorsOrbimed
& 1 more
- Acquired byShanghai Runda Medical Technology
(Jun 2016)
Products & Services of Response Biomedical
Response Biomedical offers a comprehensive portfolio of products and services, including RAMP Tests, RAMP 200, and COVID-19 Antigen Test.
Rapid quantitative tests for cardiovascular and infectious diseases
Self-calibrating system for acute care diagnostics
Rapid test for detecting COVID-19 antigens
Apps and channels of Response Biomedical
its YouTube channel Response Biomedical has 136 subscribers and 15 videos.
Videos from Response Biomedical
The most watched videos on Response Biomedical's YouTube channel, Response Biomedical (136 subscribers). Click a video to play it here.
More on Response Biomedical.
Funding Insights of Response Biomedical
- Total Rounds 3
- Last Round Post-IPO — $3.12M
- First Round $3.92M
(May 2009)
All 3 funding rounds of Response Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2013 | $3.12M | Post-IPO | – | – | – |
| Aug 2010 | $7.72M | Post-IPO | – | – | – |
| May 2009 | $3.92M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Response Biomedical
Response Biomedical has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed and Shanghai Runda Medical Technology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
In-vitro diagnostic products and services are supplied to laboratories. | 1999 | rundamedical.com | Shanghai, China |
Investor details for Response Biomedical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Response Biomedical
8 people are tracked at Response Biomedical (2 in leadership, 6 in team).
| Name | Role | Group |
|---|---|---|
Eric Whitters | Chief Operating Officer | Leadership |
Priscila Lopes | Director Of Operations | Leadership |
Esten Williams | Product Development Manager | Team |
Shih-Fong Huang | Production Technician | Team |
Hector Moncada Hernandez | Product Development Associate | Team |
Megan Cheng | Clinical Support Manager | Team |
James Tung | Instrument And Integration Manager | Team |
Rupinder Kaur | People And Culture Manager | Team |
Complete people profiles for Response Biomedical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Response Biomedical
5 dated milestones of Response Biomedical across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Response Biomedical is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $3.9M.
- Funding Latest funding round, Post-IPO, of $3.1M.
- Exit Acquired by Shanghai Runda Medical Technology.
Web traffic of Response Biomedical
The website of Response Biomedical (responsebio.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▲ 5.8% vs previous month
Websites whose visitors overlap most with Response Biomedical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ortoped.ca | 100% | 13.3K | #1,501,078 | View details | |
labtestsonline.org | labtestsonline.org | 91% | #1,997,139 | – | |
medisave.co.uk | medisave.co.uk | 73% | #107,049 | – | |
brilintatouchpoints.com | brilintatouchpoints.com | 60% | – | ||
| singulex.com | 57% | 1.3K | #13,700,698 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Response Biomedical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Response Biomedical
Complete news archive for Response Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Response Biomedical
Response Biomedical was founded in 1992 and raised its 1st funding round 17 years after it was founded.
Response Biomedical is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP platform for clinical and environmental applications. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use. The lateral flow based tests are available for diagnosis of Cardiovascular diseases and Infectious diseases.The RAMP system consists of a reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP clinical tests are commercially available for the early detection of heart attack and congestive heart failure through their commercial partners and distributors. In the non-clinical market, RAMP Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Response has achieved CE Marking for its readers and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.
Response Biomedical offers RAMP Tests, RAMP 200, and COVID-19 Antigen Test.
Response Biomedical has 2 investors. Key investors include Orbimed, and Shanghai Runda Medical Technology.
Response Biomedical operates through Response Biomedical Corp.
Yes. Response Biomedical was acquired by Shanghai Runda Medical Technology in June 2016.